Athira (ATHA): Alzheimer's treatment did not meet endpoint in mid-stage trial

• The results indicated Athira's lead drug, ATH-1017, also called fosgonimeton, didn't have a statistically significant impact on working memory processing speed or cognition when compared with a placebo after 26 weeks.
 

 

 

 

Mark Litton, Athira's CEO, says the company is in a "fortuitous situation" despite the disappointing results.